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OBJECTIVES We sought to investigate the clinical and echocardiographic (echo) characteristics of
metastatic carcinoid tumor in the heart.
BACKGROUND Right-sided valvular dysfunction is the hallmark of carcinoid heart disease. Cardiac metas-
tases are uncommon in carcinoid syndrome. Features of patients with metastatic carcinoid
tumor involving the heart (MCH) have not been well described.
METHODS From 1985 through 1999, 11 patients (8 male, 3 female), mean age  standard deviation, 58
 6 years, were seen who had pathologically confirmed MCH. All patients had echoes, which
were reviewed retrospectively.
RESULTS All patients with MCH had carcinoid syndrome. The primary carcinoid tumor was in the
small bowel in 83% of patients, and all patients had hepatic metastases. On pathologic review,
the 11 patients had 15 MCH tumors. All metastases were intramyocardial. The MCH
involved the right ventricle in 40%, left ventricle in 53%, and ventricular septum in 7%. The
average size of macroscopic tumors was 1.8  1.2 cm. Nine MCH tumors were detected by
echo in 6 of the 11 patients (55%). Mean echo-detected tumor size was 2.4 cm (range, 1.2
to 4). All tumors noted by echo were well circumscribed, non-infiltrating, and homogeneous.
In the 5 other patients, review of autopsy records revealed 6 macroscopic tumors, mean size
0.35 cm (range, 0.2 to 0.4), none detected by echo even retrospectively. Carcinoid valve disease
was present in 8 of the 11 MCH patients. The tricuspid valve was affected in all 8 patients (73%),
pulmonary valve in 7 (64%), and left sided valves in 4 (36%) All patients with MCH identified
by echo had cardiac surgery, 3 primarily for carcinoid valve disease and 2 for non-carcinoid cardiac
disease; in 1 patient, MCH was the primary indication for cardiac surgery.
CONCLUSIONS MCH is uncommon but can be easily identified by echo if tumor size is 1.0 cm. In patients
without valvular dysfunction, MCH may be the only manifestation of carcinoid heart disease.
A search for MCH should be an integral part of the echo exam in patients with carcinoid
syndrome. (J Am Coll Cardiol 2002;40:1328–32) © 2002 by the American College of
Cardiology Foundation
Myocardial metastatic cardiac tumors occur in 2% to 20% of
patients with metastatic cancer. The most common primary
tumors that metastasize to the heart are breast, lung, and
malignant melanoma (1). Carcinoid tumors are rare, arising
in 1.2 to 2.1/100,000 persons in the general population per
year (2). Clinically, in 20% to 30% of patients the initial
presentation results from peptide production, that is, carci-
noid syndrome. The malignant carcinoid syndrome consists
of flushing, gastrointestinal hypermotility (secretory diar-
rhea), bronchospasm, and carcinoid heart disease. The
diagnosis of carcinoid syndrome is usually suspected by
clinical features and confirmed by increased levels of the
byproduct of serotonin metabolism, 5-hydroxyindoleacetic
acid (5-HIAA). Right-sided valvular dysfunction is the
hallmark of carcinoid heart disease. Although carcinoid
tumors have been described in almost every organ, there are
few reported cases of confirmed carcinoid metastasis to the
heart (3–9). The overall incidence of myocardial carcinoid
metastases among patients with metastatic carcinoid disease
is about 4% (9). There have been no series reporting the
clinical and tumor characteristics along with echocardio-
graphic (echo) and pathologic features of metastatic carci-
noid to the heart.
To further investigate the clinical and echocardiographic
characteristics of metastatic carcinoid tumor in the heart, we
reviewed the Mayo Clinic experience with carcinoid from
1985 through 1999. The echo database (243 patients),
patient charts, pathologic records (15 patients), and autopsy
records (45 patients) pertaining to carcinoid disease were
reviewed. Specifically, we reviewed (1) the natural history of
patients with metastatic carcinoid tumor to the heart, (2)
the usefulness of echo in making the diagnosis, and (3) the
clinical course of patients with myocardial metastases.
METHODS
Selection of patients. From 1985 through 1999, 243
patients with carcinoid heart disease were seen. Of these, 11
patients (8 male, 3 female; mean age  standard of deviation,
58 6 years) were identified who had pathologic confirmation
of metastatic carcinoid tumor involving the heart. All patients
had known carcinoid tumors, and all had echo evaluation for
valvular carcinoid disease. Five patients had no echo evi-
dence of metastatic carcinoid to the heart, and in these
patients myocardial metastases were identified at autopsy.
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Clinical and Laboratory Findings All patients’ clinical
records were reviewed, including initial presentation and
subsequent course. All patients had chest radiography,
electrocardiogram, urinary 5-HIAA levels, and comprehen-
sive 2-dimensional and Doppler echo examination. All
echoes were retrospectively reviewed.
Pathologic Findings Surgical pathologic and autopsy re-
ports were reviewed to assess the gross and microscopic
pathology. Microscopic slides were prepared with
hematoxylin-eosin, Masson trichrome, and Verhoeff-van
Gieson stains.
RESULTS
Clinical features. All patients had symptomatic malignant
carcinoid syndrome, confirmed by increased levels of urinary
5-HIAA (Table 1). The mean urinary 5-HIAA level was
255 181 mg/24 h (normal 6 mg/24 h). All patients had
1 or more of the classic symptoms associated with malignant
carcinoid syndrome—most commonly flushing, in 9 of the
11 patients (82%), followed by diarrhea in 8 (73%) and
dyspnea in 6 (55%). Average patient age at diagnosis of
carcinoid syndrome was 52  10 years. The time from
diagnosis of carcinoid syndrome to diagnosis of metastatic
carcinoid tumor to the heart (either by echo or autopsy) was
5.6  3.9 years. Three patients were alive at the time of this
study. The average age of patients at death was 58  11
years. The average time from diagnosis of carcinoid syn-
drome to death was 9.5  4 years and that from diagnosis
of metastatic carcinoid tumor to the heart to death 6.3  5
years. In 5 of the 11 patients (45%), the diagnosis of
metastatic carcinoid tumor to the heart was first made at
autopsy. The primary carcinoid tumor was identified in all
11 patients (Table 1). All primary tumors were in the
gastrointestinal tract; 9 (82%) in the ileum, 1 in the rectum,
and 1 in the cecum. All patients had hepatic carcinoid
metastases.
Surgical management. All patients with echo evidence of
a cardiac tumor had cardiac surgery, with removal (n 8) or
biopsy of the carcinoid metastasis. Additional cardiac sur-
gical procedures were performed in five patients; in three
patients for carcinoid valve disease, in two patients for
noncarcinoid cardiac disease (coronary artery disease in one
patient and mitral valve prolapse with mitral regurgitation in
the other), and in one patient for metastatic carcinoid tumor
to the heart. Surgical removal of the tumor was accom-
plished in five of six patients (83%); the other patient had
tumor biopsy.
Echocardiographic features. Nine metastatic carcinoid tu-
mors to the heart were identified by echo in 6 of the 11
patients (55%). Two of these patients had multiple tumors;
2 tumors in 1 patient and 3 in the other. Four of the 9
tumors were located in the left ventricular myocardium, 4 in
the right ventricular myocardium, and 1 in the interventric-
ular septum. The mean echo-detected tumor size was 2.4 cm
(range, 1.2 to 4 cm). All metastatic tumors noted by echo were
well circumscribed, non-infiltrating, and homogeneous (Fig.
1). No metastases were pedunculated or mobile. All of these
patients went on to have cardiac surgery.
In 5 of the 11 patients, 6 macroscopic tumors were noted
on autopsy, with a mean size of 0.35 cm (range, 0.2 to 0.4
cm). None of these tumors was detectable by echo, even
with retrospective review. The average time between echo
examination and autopsy diagnosis of metastatic carcinoid
tumor was 45 days (range, 1 to 193 days). Multiple
microscopic tumors were present in 2 patients. Four of the
6 tumors were located in the left ventricle and 1 each in the
right ventricle and the interventricular septum.
Carcinoid valve disease was present in 8 of the 11 patients
(73%) (Table 2). The tricuspid valve was affected in all 8
patients, the pulmonary valve in 7 (64%), the mitral valve in
3 (27%), and the aortic valve in 2 (18%). Three patients had
no evidence of carcinoid valve disease.
Systolic function was preserved, with an average ejection
Abbreviations and Acronyms
5-HIAA  5-hydroxyindoleacetic acid
MCH  metastatic carcinoid tumor involving the
heart
Table 1. Clinical Features of MCH
Patient Gender
Age at Carcinoid
Symptom Onset, yr
Age at MCH
Diagnosis, yr
Age at
Death, yr
Time from Symptom
Onset to Diagnosis, yr
Time from Symptom
Onset to Death, yr
5-HIAA,
mg/24 h
Site of Primary
Tumor
1 M 45 53 59 8 14 472 Ileum
2 M 67 68 1 119 Ileum
3 M 52 61 62 9 10 642 Ileum
4 M 58 60 72 2 14 248 Ileum
5 M 62 62 0 220 Ileum
6 F 62 66 4 106 Cecum
7 F 42 45 45 3 3 420 Ileum
8 M 53 62 62 9 9 118 Ileum
9 M 34 39 39 5 5 78 Rectum
10 F 51 63 63 12 12 148 Ileum
11 M 53 62 62 9 9 235 Ileum
Average 52.6 58.2 58 5.6 9.5 255
5-HIAA  hydroxyindoleacetic acid; MCH  metastatic carcinoid tumor to the heart.
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fraction of 62  9%. A patent foramen ovale was detected
by echo in 3 patients (1 by transesophageal and 2 by
transthoracic echo). Two of these patients had evidence of
left-sided carcinoid valvular heart disease.
Pathology. On pathologic review, the 11 patients had 15
metastatic carcinoid tumors (Table 2). All of the metastases
were intramyocardial (Fig. 2). The average size of macro-
scopic tumors was 1.8 1.2 cm (Fig. 3). The location of the
15 tumors was the right ventricle in 6 (40%), the left
ventricle in 8 (53%), and the ventricular septum in 1 (7%).
The carcinoid valve pathology was consistent with gross
thickening and presence of carcinoid plaques in the involved
valves. Valve and metastases noted by echo were confirmed
by pathologic review in all patients.
DISCUSSION
To our knowledge, it is the first series to describe the echo
features of metastatic carcinoid tumor involving the heart.
Of the 243 patients seen with carcinoid heart disease from
1985 through 1999, 11 (4%) were identified as having
metastatic carcinoid tumor involving the heart. Carcinoid
tumor infiltration of the heart as the only cardiac manifes-
tation of carcinoid disease is a significant finding. It under-
scores the importance of a complete echo evaluation in
carcinoid syndrome.
Left-sided valvular pathologic changes occur in fewer
than 10% of carcinoid patients who have cardiac involve-
ment (9). It is most commonly found among those with an
Figure 1. Echocardiographic features. (A) Metastatic carcinoid tumors (M) affecting the left and right ventricles. (B) Metastatic tumor affecting the right
ventricular outflow tract. Ao  aorta; LV  left ventricle.
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intracardiac shunt, which allows the serotonin-rich blood to
enter the left heart chambers without first passing through
the lungs. Left-sided valvular disease in carcinoid syndrome
may also occur in the presence of a primary bronchial
carcinoid. Occasionally, left-sided valvular disease is seen in
patients who have severe, poorly controlled carcinoid syn-
drome with high levels of circulating serotonin. In fact as
recently shown, patients with left-sided valvular heart in the
absence of a patent foramen ovale the circulating serotonins
were significantly higher (10). Left-sided carcinoid valvular
disease is characterized by regurgitation rather than stenosis
of the valve.
In this series of patients with myocardial metastases,
left-sided valvular involvement was present in 36%.
The present study is the first to provide echo features
along with pathologic correlation and clinical outcome of
patients with this rare entity. The metastatic carcinoid
tumor has a recognizable appearance and can be readily
detected by echo, provided that the tumor is at least 1.0 cm
in size. Metastatic carcinoid tumor to the heart may be the
only echo manifestation of carcinoid heart disease.
Clinically, the biochemical markers of disease (urine
5-HIAA), patient age, location of the primary tumor,
duration of symptoms, and types of symptoms were similar
to those of patients who historically had valvular carcinoid
heart disease rather than to those who had carcinoid
syndrome without cardiac involvement. In our series, pa-
tient survival from the time of diagnosis of carcinoid
syndrome was 9.5  4 years and diagnosis of metastatic
carcinoid tumor was 6.3  5 years. Comparison of survival
Table 2. Echocardiographic and Pathologic Features
Patient
Valvular
Involvement EF, % PFO
No. of
Masses
Location of Metastases
LV RV IS
Echo detectable
1 T,P,M 65 No 2 1 1
2 T,P 64 Yes 1 1
3 T,P 66 No 1 1
4 None 68 No 3 2 1
5 None 77 No 1 1
6 T,P,A 70 Yes 1 1
Subtotal 9 4 4 1
Not echo detectable
7 T,P,M,A 60 Yes 2 1 1
8 T,M 55 No 1 1
9 None 60 No 1 1
10 T,P 40 No 1 1
11 T,P 60 No 1 1
Subtotal 6 4 2
Total/average 62.3 15 8 6 1
A  aortic; EF  ejection fraction; IS  interventricular septum; LV  left ventricle; M  mitral; P  pulmonary; PFO 
patent foramen ovale; RV  right ventricle; T  tricuspid.
Figure 2. Metastatic carcinoid tumor to the right ventricle (Hematoxylin-eosin  10).
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with historical controls was confounded by the small num-
ber of patients in our study, and five of our patients being
diagnosed at autopsy.
Most of the patients with metastatic carcinoid tumors at
autopsy or surgery had metastases involving the left ventri-
cle, even though 8 of 11 patients had right-sided valvular
disease. In two of the three patients without carcinoid
valvular disease (by echo or pathology), the metastatic tumor
was located in the left ventricle, perhaps because valvular
carcinoid is related to the presence of active biochemical
factors (such as serotonin). The presence and location of
metastatic carcinoid tumor may also be related to the
rheologic and mechanical factors in the milieu.
In conclusion, on echo evaluation, metastatic carcinoid
tumor appears as a homogeneous, circumscribed, non-
infiltrating mass affecting the left or right ventricular myo-
cardium. Although metastatic carcinoid tumor is uncom-
mon, it has echo characteristics that make it easily
identifiable when it is 1.0 cm or larger. Metastatic carcinoid
tumor may be the only manifestation of carcinoid heart
disease. The comprehensive echo assessment of the patient
with carcinoid disease should include a search for carcinoid
cardiac metastases, even in the absence of carcinoid valvular
disease.
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Figure 3. Surgical specimen of metastatic carcinoid tumor to the right
ventricle.
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